Yes, I recall him mentioning the locations and a f

Yes, I recall him mentioning the locations and a few names. I recall in one interview where RP was talking about the best CTC guy in the country and mentioned Cristofanilli but it is also noted in the following PRs (from late 2018) as him being the trial PI.

“I’m delighted to announce that Dr. Massimo Cristofanilli, an internationally renowned medical oncologist and thought leader on treatment options for women with breast cancer, has agreed to serve as the trial’s principal investigator. He will lead the trial’s team of investigators, which will include distinguished oncologists at other academic cancer centers,” added Dr. Pourhassan. Dr. Cristofanilli is Professor of Medicine (Division of Hematology and Oncology), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine in Chicago.

https://ir.cytodyn.com/press-releases/detail/...leronlimab

In contrast with small molecule inhibitors of CCR5, we believe that the use of a monoclonal antibody such as PRO 140 can offer increased efficacy and a better safety profile,” stated Dr. Massimo Cristofanilli, a leader in the breast oncology field, medical oncologist and the Principal Investigator of the CytoDyn clinical trial notes. “As it stands now, TNBC is still an unmet medical need because it remains highly metastatic and difficult to treat. Novel therapies have to focus on targeting the metastatic process to improve outcome of these patients. In this study, we will measure clinical and biological endpoints, in addition to progression free survival, we will monitor Circulating Tumor Cells (CTC)’s in the blood,” added Dr. Massimo Cristofanilli.

https://ir.cytodyn.com/press-releases/detail/...-in-cancer

Please do your own due diligence. All my posts and comments are not to be considered investment advice.